扩大筛查成功率以降低主动脉瘤死亡率--进展解读与新战线。

IF 7.3 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Trends in Cardiovascular Medicine Pub Date : 2024-12-13 DOI:10.1016/j.tcm.2024.12.004
Nobel Chenggong Zong, Kai Huang, Xia Yang, Hua Cai
{"title":"扩大筛查成功率以降低主动脉瘤死亡率--进展解读与新战线。","authors":"Nobel Chenggong Zong, Kai Huang, Xia Yang, Hua Cai","doi":"10.1016/j.tcm.2024.12.004","DOIUrl":null,"url":null,"abstract":"<p><p>Aortic aneurysm is a leading cause of death across the world. Many victicms carry it without knowing. Ruputre of aortic aneurysms leads to devastating sudden death. This brings trauma to families and our society. Based upon sound results out of several cohort studies, US Preventative Services Task Force (USPST) crafted the 1st nationwide abdominal aorta aneurysm (AAA) screening program in 2005. It was renewed and expanded in each of the subsequent revisions in 2014 and 2019. UK and Sweden estalished their own programs as well. Since then, a significant decline in AAA prevalence and mortality has been observed. Two decades into the practice, the state of the art on diagonstics, surgical approaches, and pharmacological options have drastically changed. Patients previously ineligible for treatment or inconclusive on diagnostics now have valid options. The screening program is on the verge for a bold expansion. In this review, we summarize the chroncles leading to the inception of the screening programs, progress in interpretation after implementation including gains, gaps and controversies, advents of new technologies and approaches, new fronts facing us, as well as priorities to be addressed in future phases. Particularly, screening asssys with a clinically tested biomarker, tetrahydrobiopterin (H<sub>4</sub>B), enables unpresended accessibility, consistency and throughput to accommodate the needs of a larger population. Furthermore, patients with AAAs at size below the eligibility threhold for surgical intervention (e.g., < 5.5 cm) can be treated with novel oral medications. Confronting factors such as changing demographics and COVID-19 aftermath are putting up new challenges. Nevertheless, running a program at national scale demands both unwavering commitment and agile fine-tuning. Technical innovation will be an indispensable chapter of its continued success. The burden of aortic aneurysm-led sudden death is too heavy for any family and the society to bear; it is time to step up our resolve with additional capacities as discussed in the present review.</p>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":" ","pages":""},"PeriodicalIF":7.3000,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Expand the success of routine screening to reduce aortic aneurysm mortality: progress interpretation and new fronts.\",\"authors\":\"Nobel Chenggong Zong, Kai Huang, Xia Yang, Hua Cai\",\"doi\":\"10.1016/j.tcm.2024.12.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Aortic aneurysm is a leading cause of death across the world. Many victicms carry it without knowing. Ruputre of aortic aneurysms leads to devastating sudden death. This brings trauma to families and our society. Based upon sound results out of several cohort studies, US Preventative Services Task Force (USPST) crafted the 1st nationwide abdominal aorta aneurysm (AAA) screening program in 2005. It was renewed and expanded in each of the subsequent revisions in 2014 and 2019. UK and Sweden estalished their own programs as well. Since then, a significant decline in AAA prevalence and mortality has been observed. Two decades into the practice, the state of the art on diagonstics, surgical approaches, and pharmacological options have drastically changed. Patients previously ineligible for treatment or inconclusive on diagnostics now have valid options. The screening program is on the verge for a bold expansion. In this review, we summarize the chroncles leading to the inception of the screening programs, progress in interpretation after implementation including gains, gaps and controversies, advents of new technologies and approaches, new fronts facing us, as well as priorities to be addressed in future phases. Particularly, screening asssys with a clinically tested biomarker, tetrahydrobiopterin (H<sub>4</sub>B), enables unpresended accessibility, consistency and throughput to accommodate the needs of a larger population. Furthermore, patients with AAAs at size below the eligibility threhold for surgical intervention (e.g., < 5.5 cm) can be treated with novel oral medications. Confronting factors such as changing demographics and COVID-19 aftermath are putting up new challenges. Nevertheless, running a program at national scale demands both unwavering commitment and agile fine-tuning. Technical innovation will be an indispensable chapter of its continued success. The burden of aortic aneurysm-led sudden death is too heavy for any family and the society to bear; it is time to step up our resolve with additional capacities as discussed in the present review.</p>\",\"PeriodicalId\":51199,\"journal\":{\"name\":\"Trends in Cardiovascular Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":7.3000,\"publicationDate\":\"2024-12-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in Cardiovascular Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.tcm.2024.12.004\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.tcm.2024.12.004","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

主动脉瘤是导致全球死亡的主要原因。许多人在不知情的情况下患上了这种疾病。主动脉瘤破裂会导致毁灭性的猝死。这给家庭和社会带来了创伤。基于多项队列研究的可靠结果,美国预防服务工作组(USPST)于 2005 年制定了首个全国性的腹主动脉瘤(AAA)筛查计划。在随后的 2014 年和 2019 年的每次修订中,该计划都得到了更新和扩展。英国和瑞典也制定了自己的计划。从那时起,AAA 的发病率和死亡率都出现了显著下降。二十年来,诊断、手术方法和药物选择的技术水平发生了巨大变化。以前不符合治疗条件或诊断结果不确定的患者现在有了有效的选择。筛查计划即将大胆扩展。在这篇综述中,我们总结了导致筛查计划启动的时间顺序、实施后的进展解释(包括收获、差距和争议)、新技术和新方法的进步、我们面临的新战线以及未来阶段需要解决的优先事项。特别是,利用临床测试生物标志物四氢生物蝶呤(H4B)进行筛查分析,可实现前所未有的可及性、一致性和吞吐量,以满足更多人群的需求。此外,AAA 的大小低于手术干预资格标准(如小于 5.5 厘米)的患者可以使用新型口服药物进行治疗。面对人口结构变化和 COVID-19 后遗症等因素,我们面临着新的挑战。尽管如此,如此大规模的项目运行既需要坚定不移的承诺,也需要灵活的微调。技术创新将是项目持续成功不可或缺的一部分。主动脉瘤导致的猝死对任何一个家庭和社会来说都是沉重的负担;现在是时候加强我们的决心,提高我们的能力了,正如本综述中所讨论的那样。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Expand the success of routine screening to reduce aortic aneurysm mortality: progress interpretation and new fronts.

Aortic aneurysm is a leading cause of death across the world. Many victicms carry it without knowing. Ruputre of aortic aneurysms leads to devastating sudden death. This brings trauma to families and our society. Based upon sound results out of several cohort studies, US Preventative Services Task Force (USPST) crafted the 1st nationwide abdominal aorta aneurysm (AAA) screening program in 2005. It was renewed and expanded in each of the subsequent revisions in 2014 and 2019. UK and Sweden estalished their own programs as well. Since then, a significant decline in AAA prevalence and mortality has been observed. Two decades into the practice, the state of the art on diagonstics, surgical approaches, and pharmacological options have drastically changed. Patients previously ineligible for treatment or inconclusive on diagnostics now have valid options. The screening program is on the verge for a bold expansion. In this review, we summarize the chroncles leading to the inception of the screening programs, progress in interpretation after implementation including gains, gaps and controversies, advents of new technologies and approaches, new fronts facing us, as well as priorities to be addressed in future phases. Particularly, screening asssys with a clinically tested biomarker, tetrahydrobiopterin (H4B), enables unpresended accessibility, consistency and throughput to accommodate the needs of a larger population. Furthermore, patients with AAAs at size below the eligibility threhold for surgical intervention (e.g., < 5.5 cm) can be treated with novel oral medications. Confronting factors such as changing demographics and COVID-19 aftermath are putting up new challenges. Nevertheless, running a program at national scale demands both unwavering commitment and agile fine-tuning. Technical innovation will be an indispensable chapter of its continued success. The burden of aortic aneurysm-led sudden death is too heavy for any family and the society to bear; it is time to step up our resolve with additional capacities as discussed in the present review.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Trends in Cardiovascular Medicine
Trends in Cardiovascular Medicine 医学-心血管系统
CiteScore
18.70
自引率
2.20%
发文量
143
审稿时长
21 days
期刊介绍: Trends in Cardiovascular Medicine delivers comprehensive, state-of-the-art reviews of scientific advancements in cardiovascular medicine, penned and scrutinized by internationally renowned experts. The articles provide authoritative insights into various topics, encompassing basic mechanisms, diagnosis, treatment, and prognosis of heart and blood vessel disorders, catering to clinicians and basic scientists alike. The journal covers a wide spectrum of cardiology, offering profound insights into aspects ranging from arrhythmias to vasculopathies.
期刊最新文献
Editorial Commentary: The Relationship Between Alcohol Intake and Cardiovascular Health: Gaps in Knowledge. Cardiovascular-liver-metabolic health: Time to integrate liver assessment into cardiology practice? Enhancing cardiovascular prevention: Multimodal physical activity is powerful, but individualisation is the key to better outcomes. Atrial fibrillation versus atrial myopathy in thrombogenesis: Two sides of the same coin? Metabolic Dysfunction-Associated Steatotic Liver Disease and the Cardiovascular System.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1